000276181 001__ 276181
000276181 005__ 20250209000727.0
000276181 0247_ $$2doi$$a10.3390/geriatrics10010014
000276181 0247_ $$2pmid$$apmid:39846584
000276181 0247_ $$2altmetric$$aaltmetric:173447168
000276181 037__ $$aDZNE-2025-00249
000276181 041__ $$aEnglish
000276181 082__ $$a610
000276181 1001_ $$00000-0002-2958-5220$$aLiampas, Ioannis$$b0
000276181 245__ $$aGenetic Predisposition to Hippocampal Atrophy and Risk of Amnestic Mild Cognitive Impairment and Alzheimer's Dementia.
000276181 260__ $$aBasel$$bMDPI$$c2025
000276181 3367_ $$2DRIVER$$aarticle
000276181 3367_ $$2DataCite$$aOutput Types/Journal article
000276181 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738669834_16422
000276181 3367_ $$2BibTeX$$aARTICLE
000276181 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276181 3367_ $$00$$2EndNote$$aJournal Article
000276181 520__ $$aThere is a paucity of evidence on the association between genetic propensity for hippocampal atrophy with cognitive outcomes. Therefore, we examined the relationship of the polygenic risk score for hippocampal atrophy (PRShp) with the incidence of amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD) as well as the rates of cognitive decline.Participants were drawn from the population-based HELIAD cohort. Comprehensive neuropsychological assessments were performed at baseline and at follow-up. PRShp was derived from the summary statistics of a large genome-wide association study for hippocampal volume. Cox proportional hazards models as well as generalized estimating equations (GEEs) were used to evaluate the association of PRShp with the combined incidence of aMCI/AD and cognitive changes over time, respectively. All models were adjusted for age, sex, education, and apolipoprotein E (APOE) genotype.Our analysis included 618 older adults, among whom 73 developed aMCI/AD after an average follow-up of 2.96 ± 0.8 years. Each additional SD of PRShp elevated the relative hazard for incident aMCI/AD by 46%. Participants at the top quartile of PRShp had an almost three times higher risk of converting to aMCI/AD compared to the lowest quartile group. Higher PRShp scores were also linked to steeper global cognitive and memory decline. The impact of PRShp was greater among women and younger adults.Our findings support the association of PRShp with aMCI/AD incidence and with global cognitive and memory decline over time. The PRS association was sex- and age-dependent, suggesting that these factors should be considered in genetic modelling for AD.
000276181 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000276181 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276181 650_7 $$2Other$$aAlzheimer’s disease
000276181 650_7 $$2Other$$acognitive decline
000276181 650_7 $$2Other$$ahippocampal atrophy
000276181 650_7 $$2Other$$apolygenic risk score
000276181 7001_ $$aSiokas, Vasileios$$b1
000276181 7001_ $$aMourtzi, Niki$$b2
000276181 7001_ $$aCharisis, Sokratis$$b3
000276181 7001_ $$00009-0009-7316-0471$$aSampatakakis, Stefanos N$$b4
000276181 7001_ $$aFoukarakis, Ioannis$$b5
000276181 7001_ $$aHatzimanolis, Alex$$b6
000276181 7001_ $$0P:(DE-2719)2812825$$aRamirez, Alfredo$$b7
000276181 7001_ $$aLambert, Jean-Charles$$b8
000276181 7001_ $$00000-0003-2171-7337$$aYannakoulia, Mary$$b9
000276181 7001_ $$00000-0001-8790-1220$$aKosmidis, Mary H$$b10
000276181 7001_ $$00000-0003-2957-641X$$aDardiotis, Efthimios$$b11
000276181 7001_ $$00000-0001-5386-4273$$aHadjigeorgiou, Georgios M$$b12
000276181 7001_ $$aSakka, Paraskevi$$b13
000276181 7001_ $$00000-0003-2549-6834$$aRouskas, Konstantinos$$b14
000276181 7001_ $$aScarmeas, Nikolaos$$b15
000276181 773__ $$0PERI:(DE-600)2934571-6$$a10.3390/geriatrics10010014$$gVol. 10, no. 1, p. 14 -$$n1$$p14$$tGeriatrics$$v10$$x2308-3417$$y2025
000276181 8564_ $$uhttps://pub.dzne.de/record/276181/files/DZNE-2025-00249_SUPP.zip
000276181 8564_ $$uhttps://pub.dzne.de/record/276181/files/DZNE-2025-00249.pdf$$yOpenAccess
000276181 8564_ $$uhttps://pub.dzne.de/record/276181/files/DZNE-2025-00249.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276181 909CO $$ooai:pub.dzne.de:276181$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000276181 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000276181 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000276181 9141_ $$y2025
000276181 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000276181 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000276181 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-28
000276181 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:32:04Z
000276181 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:32:04Z
000276181 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000276181 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000276181 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000276181 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:32:04Z
000276181 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000276181 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000276181 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000276181 9201_ $$0I:(DE-2719)1011101$$kPatient Studies (Bonn)$$lPatient Studies (Bonn)$$x0
000276181 980__ $$ajournal
000276181 980__ $$aVDB
000276181 980__ $$aUNRESTRICTED
000276181 980__ $$aI:(DE-2719)1011101
000276181 9801_ $$aFullTexts